Abstracts tagged "systemic sclerosis and transplantation"

Abstract Number: 902 • 2018 ACR/ARHP Annual Meeting
Longitudinal Trends in Clinical Disease Features after Myeloablative Autologous Stem-Cell Transplantation or Cyclophosphamide in Severe Scleroderma
Lynette Keyes-Elstein¹, Ellen Goldmuntz², Ashley Pinckney³, Leslie Crofford⁴, Daniel E. Furst⁵, Maureen D. Mayes⁶, Peter McSweeney⁷, Richard Nash⁷, Beverly Welch⁸ and Keith Sullivan⁹, ¹Biostatistics, Rho Federal Systems, Inc, Chapel Hill, NC, ²NIAID, NIH, Bethesda, MD, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁵UCLA, Los Angeles, CA, ⁶Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁷Colorado Blood Cancer Institute, Denver, CO, ⁸6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁹Duke University Medical Center, Durham, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) study established the long-term superiority of hematopoietic stem cell transplant (HSCT) over cyclophosphamide (CYC) [Sullivan KM, et al.…
Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting
Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide
Keith Sullivan¹, Ashley Pinckney², Ellen Goldmuntz³, Beverly Welch⁴, Dinesh Khanna⁵, Robert W. Simms⁶, Suzanne Kafaja⁷, George Georges⁸, Jan Storek⁹, Mary Ellen Csuka¹⁰, Richard Nash¹¹, Daniel E. Furst¹², Leslie Crofford¹³, Peter McSweeney¹¹, Maureen D. Mayes¹⁴ and Lynette Keyes-Elstein¹⁵, ¹Duke University Medical Center, Durham, NC, ²Rho Federal Systems, Inc., Chapel Hill, NC, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁸Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Medicine, Medical College of Wisconsin, Milwaukee, WI, ¹¹Colorado Blood Cancer Institute, Denver, CO, ¹²University of Washington, Seattle, WA, ¹³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁴Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁵Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…
Abstract Number: 2675 • 2017 ACR/ARHP Annual Meeting
Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014
Osman Bhatty¹, Rouhin Sen¹, Douglas Moore² and Joseph Nahas³, ¹Department of Medicine, CHI Creighton University Medical Center, Omaha, NE, ²Department of Pulmonary/Critical Care, CHI Creighton University Medical Center, Omaha, NE, ³Department of Rheumatology, CHI Creighton University Medical Center, Omaha, NE
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease once characterized by high mortality rates now with better outcomes. Pulmonary disease has overtaken renal failure…
Abstract Number: 851 • 2016 ACR/ARHP Annual Meeting
Perioral Autologous FAT Transplantation Is More Effective THAN Hyaluronic Acid Filler on Scleroderma Skin Fibrosis: Results from a LONG TERM Controlled Study
Nicoletta Del Papa¹, Eleonora Zaccara¹, Romina Andracco¹, Wanda Maglione¹, Francesca Pignataro¹, Fabio Caviggioli², Gabriele Di Luca³, Antonina Prafioriti⁴ and Claudio Vitali⁵, ¹Dept. Rheumatology, G. Pini Hospital, Milano, Italy, ²UOC Chirurgia Plastica, UOC Chirurgia Plastica, Multimedica Holding SpA, Milano, Italy, ³UOS Chirurgia Vascolare,, Osp. G. Pini, Milano, Italy, ⁴Pathology Unit, Istituto G.Pini, Milan, Italy, ⁵Rheumatology Section, Istituto San Giuseppe, Como, Italy
Background/Purpose: Autologous fat tissue grafting (AFTG) has been successfully used in the treatment of different sclerotic conditions, including scleroderma. We evaluated in patients with SSc…
Abstract Number: 2697 • 2014 ACR/ARHP Annual Meeting
Gender Disparities in Lung Transplantation in Patients with Systemic Sclerosis-Related Interstitial Lung Disease and Pulmonary Hypertension
Elizabeth Volkmann¹, Daniel E. Furst², Rajeev Saggar³, Philip J. Clements⁴, Bryant Torres⁵, Lynne Yoder¹ and Rajan Saggar¹, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of California, Los Angeles, CA, ³Cardiothoracic Surgery, University of Arizona College of Medicine, Phoenix, AZ, ⁴University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁵Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA
Background/Purpose: Lung transplantation is often the most viable option for patients with severe systemic sclerosis (SSc)-associated interstitial lung disease (ILD) that is unresponsive to pharmacologic…
Abstract Number: 1797 • 2014 ACR/ARHP Annual Meeting
One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study
Elana J. Bernstein¹, Eric R. Peterson², Joan M. Bathon² and David J. Lederer², ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease…
Abstract Number: 2918 • 2013 ACR/ARHP Annual Meeting
Survival After Lung Transplantation In Systemic Sclerosis. A Systematic Review
Irfan Y. Khan¹, Lianne G. Singer², Marc de Perrot³, John T. Granton⁴, Shaf Keshavjee³, Cathy Chau⁵, Amie T. Kron⁶ and Sindhu R. Johnson⁷, ¹Medicine, Pulmonary Hypertension Programme, University Health Network, University of Toronto, Toronto, ON, Canada, ²Medicine, Division of Respirology, University of Toronto; and Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ³Medicine, Toronto Lung Transplant Program, Division of Thoracic Surgery, University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ⁵Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ⁷Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Lung transplantation is a life-saving option for systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) and interstitial lung disease (SSc-ILD) patients. Yet, there is risk…
Abstract Number: L2 • 2012 ACR/ARHP Annual Meeting
High Dose Immunoablation and Autologous Hematopoietic Stem Cell Transplantation Versus Monthly Intravenous Pulse Therapy Cyclophosphamide in Severe Systemic Sclerosis
Jacob M. van Laar¹, Dominique Farge², Jaap K. Sont³, Kamran Naraghi⁴, Zora Marjanovic⁵, Annemie Schuerwegh⁶, Madelon C. Vonk⁷, Marco Matucci-Cerinic⁸, A.E. Voskuyl⁹, Alois Gratwohl¹⁰, Alan G. Tyndall¹¹ and EBMT/EULAR Scleroderma Study Group¹², ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Internal Medicine, Hopital St Louis, Paris, France, ³Medical Decision Making, Leiden University Medical Centre, Leiden, Netherlands, ⁴Rheumatology, The James Cook University, Middlesbrough, United Kingdom, ⁵Hematology, Hopital St Antoine, Paris, France, ⁶Leids Univ Medisch Centrum, Leiden, Netherlands, ⁷Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁸Department of Biomedicine & Division of Rheumatology AOUC, University of Florence, Florence, Italy, ⁹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹⁰Hematology, University Hospital Basel, Basel, Switzerland, ¹¹Rheumatology, University of Basel, Basel, Switzerland, ¹²Rheumatology, The James Cook University Hospital, Middlesbrough, United Kingdom
Background/Purpose: High dose immunosuppressive therapy and hematopoietic stem cell transplantation (HSCT) have shown efficacy in severe systemic sclerosis (SSc) in phase I and II trials.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].